An exciting research study has concluded at Johns Hopkins University and the results could be great news for the millions of patients who suffer from Alzheimer’s dementia. Epilepsy is a common neurological disorder that affects more than 50 million …

Cell stress magnified by chronic disease All of us undergo stress, but those dealing with chronic illnesses such as cancers, diabetes, inflammatory diseases, and neurological degenerative diseases such as Parkinson’s and Alzheimer’s are at an …

From the University of Liverpool and Callaghan Innovation in New Zealand comes a study that local scientists have been developing; a new kind of chemical approach that will harness the natural ability of complex sugars in the treatment Alzheimer’s d…

Researchers at Lund University in Sweden headed by Professor Singerup Linse and Erik Helistrand have recently identified a molecular mechanism behind the crucial step in Alzheimer’s that leads to the death of brain cells. The neurological dis…

A recently completed study at the University of Exeter showed that people with long-lived parents had a twenty-four percent decreased chance of getting cancer. The parameters of ‘long-lived’ defined as mothers who lived past ninet…

Within the journal Science, University of Pittsburgh Graduate School of Public Health scientists confirm that a study performed on mouse models of Alzheimer’s disease had significantly improved brain function and memory capabilities after being trea…

At Queen Mary University in London, researchers have conducted the largest study of genetic sequencing of human diseases known to date, identifying the genetic basis of six different diseases: autoimmune thyroid disease, celiac disease, Crohn&rsquo…

A study published in the May 2013 online issue of Neurology follows researchers in Minneapolis who performed a study where 1,102 participants, of an averaged an age of 79, were followed for the span of 3.7 years and tested to … Continue reading &ra…

According to Northwestern Medicine Research, new experimental molecules have great promise in targeting enzymes in the brain that prevent memory loss in Alzheimer’s disease. Developed in D. Martin Watterson’s laboratory, the molecules ha…

Drs. David Holtzman and Mac Diamond of the Washington University School of Medicine recently published research in Neuron that outlined the process of studying mice for potential tau protein tangle treatment avenues. Tau is a toxic component of Alzheimer&…

Cedars-Sinai scientists published a study in Journal of Clinical Investigation that suggests ACE inhibitors, in the right context and at the right time, can be a good thing. Many people with high blood pressure take ACE inhibitors, medication meant…

A study conducted recently at the Univeraity of California- San Francisco published online in JAMA Internal Medicine. The research was focused in on finding a close link between diabetes and dementia. According to the journal, diabetic patients with…

Researchers at Sanford-Burnham Medical Research Institute have developed the first experimental drug named NitroMemantine that boosts brain synapses lost to Alzheimer’s disease. The medication combines two FDA-approved drugs to stop destructive casc…

Researchers at the Michigan Alzheimer’s Disease Center discovered that flavored ECGC, or epigallocatechi-3-gallate, found in green tea could bind to the toxic protein beta-amyloid and prevent its build-up. When ECGC binds to the protein, it is able …

A recent report from researchers at the Massachusetts General Hospital which identifies a protein that aids the immune system in the removal of A-beta protein from the brain, could lead to new treatments of Alzheimer’s disease. According to cocorres…

Researchers at Duke University have identified a new type of neuron within the adult brain capable of directing stem cells to make new neurons. The experiments are preliminary, but the hope is that the brain one day could be healing … Continue read…

A recent study from University of California, San Francisco scientists found that a chemical in anti-wrinkle cream could effectively prevent the death of nerve cells that had been damaged by mutations which cause an inherited form of Parkinson’s dis…

Mayo clinic researchers demonstrated within a mouse model that a synthetic peptide carrier works to deliver brain cancer chemotherapy drugs, as well as neurological medications. Neuroscientist Gobinda Sarkar, Ph.D, of the Mayo Clinic and corresponding aut…

According to research by the Washington University School of Medicine, published in Science Translational Medicine, a common antidepressant can reduce the production of brain plaques. Brain plaques correlate closely with memory problems and other cognitiv…

Welcome to Dr. Michael Mullan's website.

Michael Mullan is a biomedical researcher of the β-amyloid protein and its relation to Alzheimer’s disease. Mullan's Alzheimer research is well known among Biomedical Community. Dr. Mullan's Alzheimer research work resulted in identifying the most widely known Swiss Mutation that is present in familial form. Transgenic Animal for Alzheimer Disease uses Swiss Mutation.

Dr. Mullan is currently the directorof the Roskamp Institute in Sarasota, Florida. Under Dr. Mullan's guidelines the institute is carrying out cutting edge research in Alzheimer's, Traumatic Brain Research, Gulf War Illness and other neuropsychiatric disorder. Some of the current research areas that the institute works on:

Please visit this and other linked sites frequently to learn more about research activities at the Roskamp Institute. Also visit blogs in this site to obtain valuble information and comments by Dr. Michael Mullan